🇺🇸 FDA
Pipeline program

RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine (REPAIR GETUG P16)

ICO-2020-01 REPAIR

Phase 2 other active

Quick answer

RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine (REPAIR GETUG P16) for RElapse in previously irradiated Prostate bed is a Phase 2 program (other) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
CERO THERAPEUTICS HOLDINGS, INC.
Indication
RElapse in previously irradiated Prostate bed
Phase
Phase 2
Modality
other
Status
active

Clinical trials